Clinical Trial Update: Regression of Liver Fibrosis After Daclatasvir and Asunaprevir Treatment

View source ↗

Summary

A clinical trial update reports regression of liver fibrosis in patients with chronic hepatitis C treated with daclatasvir and asunaprevir.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Daklinza (Daclatasvir)
• Sunveva (asunaprevir)

Snippet

Sponsor: Sang Gyune Kim | Conditions: Chronic Hepatitis C | Status: UNKNOWN